Accelerated Approval: How The Aduhelm Probes Will, And Won’t, Impact The Debate

 
• By Sarah Karlin-Smith
FDA under OIG microscope (design by Nielsen Hobbs)
FDA is undergoing two reviews related to its controversial approval of Biogen’s Aduhelm. • Source: Nielsen Hobbs; the Pink Sheet | Alamy image

More from US FDA

More from Agency Leadership